These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10220610)

  • 1. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
    Jackson JD
    Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609
    [No Abstract]   [Full Text] [Related]  

  • 3. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy.
    Schrogie JJ
    Am Heart J; 1999 May; 137(5):S126-8. PubMed ID: 10220614
    [No Abstract]   [Full Text] [Related]  

  • 4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs.
    Schwartz JS
    Am Heart J; 1999 May; 137(5):S97-104. PubMed ID: 10220608
    [No Abstract]   [Full Text] [Related]  

  • 5. A call for fairness in formulary decisions.
    Levinson W; Laupacis A
    Arch Intern Med; 2006 Jan; 166(1):16-8. PubMed ID: 16401806
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacoeconomics of lipid-lowering drugs.
    Smith DG
    Curr Atheroscler Rep; 2003 Jan; 5(1):67-72. PubMed ID: 12562545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside.
    Kazi DS; Virani SS
    Prog Cardiovasc Dis; 2019; 62(5):406-413. PubMed ID: 31672610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of lipid management.
    Mullins CD
    Manag Care; 2001 Nov; 10(11 Suppl):17-8; discussion 19-24. PubMed ID: 11761626
    [No Abstract]   [Full Text] [Related]  

  • 9. Application of pharmacoeconomics to formulary management in a health system setting.
    Studdert AL; Gong CL; Srinivas S; Chin AL; Deresinski S
    Am J Health Syst Pharm; 2019 Feb; 76(6):381-386. PubMed ID: 31361838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction.
    Lewandowski CA; Kahler J
    Am Heart J; 1999 May; 137(5):S94-6. PubMed ID: 10220607
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmaco-economics of hypolipidemic agents: analysis of factors influencing the cost-effectiveness relation].
    Scheen AJ
    Rev Med Liege; 1998 May; 53(5):270-5. PubMed ID: 9689881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving use of cost-effectiveness analysis in formulary management within the Department of Veterans Affairs.
    Aspinall SL; Good CB; Glassman PA; Valentino MA
    Med Care; 2005 Jul; 43(7 Suppl):20-6. PubMed ID: 16056005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
    Detsky AS
    Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597
    [No Abstract]   [Full Text] [Related]  

  • 14. Managed care guidelines for the economic evaluation of pharmaceuticals.
    Langley PC; Martin RE
    Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
    Temple R
    Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602
    [No Abstract]   [Full Text] [Related]  

  • 16. An interactive computer system for formulary management using cost-effectiveness analysis.
    Lee JH; Glick HA; Kinosian B; Schulman KA
    MD Comput; 1995; 12(1):59-65. PubMed ID: 7854081
    [No Abstract]   [Full Text] [Related]  

  • 17. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are the new Lipid Management Guidelines good for Australia's health?
    Jackson RT
    Med J Aust; 2001 Nov; 175(9):452-3. PubMed ID: 11758069
    [No Abstract]   [Full Text] [Related]  

  • 19. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis.
    DeLong ER; Simons T
    Am Heart J; 1999 May; 137(5):S47-50. PubMed ID: 10220596
    [No Abstract]   [Full Text] [Related]  

  • 20. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care.
    Stewart A; Schmier JK; Luce BR
    Am Heart J; 1999 May; 137(5):S53-61. PubMed ID: 10220598
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.